What NanOlogy does

NanOlogy, LLC is a privately held, clinical-stage interventional oncology drug developer founded in 2015 as a joint venture among DFB Pharmaceuticals (Fort Worth, TX), CritiTech (Lawrence, KS), and US Biotest (San Luis Obispo, CA). The company is headquartered in Fort Worth, Texas, operates with 1–10 employees, and has no disclosed funding rounds, external investors, or commercial product revenue. Its purpose is to advance a local, intratumoral precision-therapy approach for solid tumors that minimizes systemic toxicity relative to conventional IV chemotherapy.

The company's core technology is the PURCISION particle-engineering platform, which uses supercritical fluid carbon dioxide to reduce taxane API crystals by up to 400-fold into stable submicron or micron particles of pure drug, forming Large Surface Area Microparticles (LSAMs) optimized for intratumoral delivery. These particles function as a depot at the disease site, releasing drug locally at high concentration while maintaining negligible systemic plasma levels. The intellectual property estate comprises over 130 issued patents globally, including composition-of-matter claims (US 9,814,685; US 10,507,195; US 10,993,927; US 11,123,322) valid through June 2036 and parallel filings in major jurisdictions. The product portfolio comprises NanoPac (submicron paclitaxel sterile suspension for intratumoral, intracystic, and inhaled delivery), NanoDoce (submicron docetaxel for intravesical use in bladder cancer), SOR007 (topical submicron paclitaxel for cutaneous metastases), and LSAM-Cisplatin for pediatric DIPG. Clinical activity spans seven completed trials and 170+ treated patients across six solid tumor types (pancreas, lung, bladder, peritoneal, ovarian, prostate, dermal) with no confirmed drug-related serious adverse events.

NanOlogy's business model is pre-commercial: revenue is generated only upon FDA approval and product launch, with no current pricing or distribution channel established. Development proceeds under the FDA 505(b)2 regulatory pathway, and GTM activity is centered on conference presentations (ASCO, BIO, ISPNO, AACR, SITC), peer-reviewed publications, and enterprise partnering outreach to pharmaceutical companies. The company appointed David J. Arthur as CEO in December 2025 and John M. Goldberg, MD as CMO in January 2026, alongside unveiling a DIPG program and planning an IND submission for mid-2026.

Name

NanOlogy

Legal name

NanOlogy, LLC

Website

https://nanology.us

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Short description

NanOlogy is a privately held, clinical-stage oncology company developing intratumoral submicron particle drug formulations (NanoPac, NanoDoce, LSAM-Cisplatin) using its PURCISION technology platform to treat solid tumors, including a new pediatric DIPG program, with minimal systemic toxicity.

Ownership category

akta.pro rank

Product category

Intratumoral Oncology Therapeutics

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Oncology Specialty Pharmaceuticals (HLAIACAA)

akta.pro secondary industry

Oncology & Hematology Pharmaceuticals (HLAIAAAC)

Keywords

• Intratumoral drug delivery
• Oncology drug development
• Submicron particle therapeutics
• Interventional oncology drugs
• Cancer microparticle platform

Headquarters

HQ city

Fort Worth

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Drug Development and Commercialization: As a pre-revenue clinical-stage oncology company, NanOlogy does not currently generate revenue. The company is advancing its LSAM investigational drug portfolio (NanoPac, NanoDoce, LSAM-Cisplatin) through clinical trials toward regulatory approval and commercial distribution. Revenue would be generated through product sales upon FDA approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

NanOlogy develops and clinically advances investigational oncology drugs in the form of Large Surface Area Microparticles (LSAMs) of proven chemotherapeutics, produced via its proprietary PURCISION™ particle engineering platform. Its drug portfolio comprises NanoPac® (submicron particle paclitaxel suspension), NanoDoce® (submicron particle docetaxel suspension), SOR007 (submicron particle paclitaxel topical ointment), and LSAM-Cisplatin, all designed for direct intratumoral, intracystic, intravesical, inhaled, or topical delivery to treat solid tumors with high local drug concentration and minimal systemic toxicity.

Product overview

NanOlogy is advancing a local precision approach for solid tumor treatment using its proprietary PURCISION™ particle engineering technology that forms Large Surface Area Microparticles (LSAMs) of cancer drugs designed for intratumoral delivery. The product portfolio includes NanoPac® (submicron particle paclitaxel sterile suspension) for multiple solid tumors, NanoDoce® (submicron particle docetaxel sterile suspension) for bladder and genitourinary cancers, SOR007 topical ointment for cutaneous metastases, and LSAM-Cisplatin for pediatric brain tumors. These investigational drugs are optimized for local delivery to maximize drug concentration at tumor sites while minimizing systemic toxicity.

Differentiator

Problem solved

Functional benefit

Brands

• NanoPac: Sterile suspension of submicron particle paclitaxel for intratumoral, intracystic, or inhaled delivery in treatment of solid tumors including pancreatic cancer, lung cancer, and pancreatic mucinous cysts.
• NanoDoce
• SOR007

Products and services

• NanoPac® Sterile suspension of submicron particle paclitaxel designed for intratumoral, intracystic, and inhalation delivery to treat solid tumors including pancreatic cancer, lung cancer, ovarian cancer, prostate cancer, and pancreatic mucinous cysts.
• NanoDoce® Sterile suspension of submicron particle docetaxel for intratumoral and intravesical delivery in bladder cancer and other genitourinary cancers.
• SOR007 Topical Ointment Submicron particle paclitaxel suspended in a topical anhydrous base for treatment of cutaneous metastases of breast cancer and actinic keratosis.
• LSAM-Cisplatin Large Surface Area Microparticle formulation of cisplatin for stereotactic intratumoral administration targeting diffuse intrinsic pontine glioma (DIPG), a rare and fatal pediatric brainstem tumor.

Quantifiable outcome

• 170+ patients treated with no confirmed drug-related serious adverse events
• +5 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core.

• CritiTech, Inc.coreTechnology or IntegrationCritiTech, Inc. of Lawrence, KS is a co-founder of NanOlogy and the licensor of the submicron particle production technology (PURCISION). The patented production process reduces taxane API crystals into stable submicron particles. CritiTech licensed the technology to DFB Soria for dermatology fields outside oncology.
• US Biotest, Inc.coreTechnology or IntegrationUS Biotest, Inc. of San Luis Obispo, CA is a co-founder of NanOlogy. The company was formed along with DFB Pharmaceuticals and CritiTech to finance and clinically develop the submicron particle technology platform for local, sustained delivery of therapeutic agents.
• DFB Soria, LLCcoreStrategic or Co-development PartnerDFB Soria is a DFB-owned affiliate that developed the topical anhydrous ointment formulation of submicron particle paclitaxel (SOR007). DFB Soria licensed the topical formulation to NanOlogy for oncology use and independently conducted Phase 2 trials in actinic keratosis. NanOlogy and DFB Soria share investigational drug programs in dermatology applications.
• Clinical Trial Sites and Medical InstitutionscoreStrategic or Co-development PartnerNanOlogy conducts clinical trials in partnership with leading medical institutions including Cedars-Sinai Medical Center (Simon Lo, MD), Baylor College of Medicine (Mohamed Othman, MD), Parkview Cancer Institute (Neil Sharma, MD), University of Florida Health (Hiren Mehta, MD), and other major cancer centers across the United States.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Iovance Biotherapeutics: Commercial-stage cell therapy company whose lead products (Amtagvi, Lifileucel) are autologous tumor-infiltrating lymphocyte therapies administered intratumorally or regionally. Comparable to NanOlogy in advancing intratumoral oncology modalities toward commercialization, though operating at much larger scale.
• Merck & Co. Global oncology incumbent whose Keytruda franchise dominates the immune checkpoint inhibitor market and would be the natural combination partner for LSAM-ICI programs. Relevant comparable for understanding how NanOlogy's combination-therapy optionality could be monetized through a major-pharma deal.
• Bristol Myers Squibb: Major oncology incumbent with checkpoint inhibitor franchises (Opdivo, Yervoy) that represent the dominant combination partner referenced in NanOlogy's LSAM-ICI patent strategy. Relevant as the most likely large-pharma acquirer or partner for NanOlogy's combination programs.
• Nanobiotix: Clinical and commercial-stage nanomedicine company whose lead asset Hensify (NbTx1) is a hafnium oxide nanoparticle injected intratumorally to enhance radiotherapy. Closely comparable to NanOlogy in using proprietary nanoparticle engineering to localize therapeutic effect within the tumor microenvironment.

Emerging players

• Phio Pharmaceuticals: Clinical-stage company developing intratumoral RNAi-based immunotherapies (INTASYL platform) designed to be administered directly into tumors. Comparable to NanOlogy as an emerging intratumoral modality developer with similar local-delivery strategic positioning.
• Lytix Biopharma: Clinical-stage immuno-oncology company developing intratumoral oncolytic peptides (LTX-315 and LTX-401) that induce tumor cell death and immune activation at the injection site. Comparable to NanOlogy as an emerging player using intratumoral administration to drive local and systemic anti-tumor immune response.
• Istari Oncology: Clinical-stage immuno-oncology company developing PVSRIPO, an intratumoral oncolytic virus therapy initially targeting recurrent glioblastoma. Comparable to NanOlogy in pursuing intratumoral administration of a locally active agent with systemic immune effects.

Direct peers

• Intensity Therapeutics: Clinical-stage oncology company developing intratumoral chemotherapy formulations (INT230-6) that combine cisplatin, vinorelbine and celecoxib for direct intratumoral injection. Most directly comparable to NanOlogy in combining reformulated cytotoxic drugs with direct local delivery to bypass systemic toxicity.
• OncoSec Medical: Clinical-stage immuno-oncology company focused on intratumoral gene electroporation delivery (TAVO), enabling local expression of IL-12 to drive immune response. Comparable to NanOlogy as a developer of intratumoral oncology therapies targeting local immune and tumor effects.
• Celsion Corporation: Clinical-stage oncology company developing ThermoDox, a heat-activated liposomal doxorubicin formulation administered intratumorally with localized hyperthermia. Shares NanOlogy's strategy of reformulating a known cytotoxic for direct local delivery to improve the therapeutic index.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/nanologyllc

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NanOlogy